Clinical Trials Logo
  1. Home
  2. Melanoma
  3. NCT03165422
  4. Details
NCT03165422 Clinical Trial

A Real-World Study of Ipilimumab Treatment After Nivolumab Treatment in Melanoma in Japan

Melanoma Clinical Trial

Official title:
A Real-World Study of Ipilimumab Treatment After Nivolumab Treatment in Melanoma in Japan

Clinical Trial Details — Status: Completed

Administrative data
NCT number NCT03165422
Other study ID # CA209-9DA
Secondary ID
Status Completed
Phase
First received
Last updated
Start date March 1, 2017
Est. completion date December 29, 2018

Study information
Verified date October 2019
Source Bristol-Myers Squibb
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

This is a medical chart review of ipilimumab treatment after nivolumab treatment in melanoma in Japan

Recruitment information / eligibility
Status Completed
Enrollment 68
Est. completion date December 29, 2018
Est. primary completion date December 29, 2018
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Adult patients > 18 years of age or older

- Diagnosis of advanced melanoma (unresectable/metastatic), alive or deceased as of date of data collection

- Treated with ipilimumab between 31-Aug-2015 and 31-Mar-2017 before or after nivolumab treatment

Exclusion Criteria:

- Patients enrolled in any clinical trials at any time

- Overlapping use of nivolumab and ipilimumab

Study Design

Related Conditions & MeSH terms

Intervention

Other:
• Non-Interventional
Non-Interventional

Locations
Country Name City State
Japan Local Institution Minato-ku Tokyo

Sponsors (2)
Lead Sponsor Collaborator
Bristol-Myers Squibb Ono Pharmaceutical Co. Ltd

Country where clinical trial is conducted

Japan, 

Outcome
Type Measure Description Time frame Safety issue
Primary Incidence of ipilimumab treatment after nivolumab treatment Approximately 19 months
Primary Incidence of nivolumab treatment after ipilimumab treatment Approximately 19 months
Primary Duration of nivolumab treatment Approximately 19 months
Primary Duration of ipilimumab treatment Approximately 19 months
Primary Duration of interval between nivolumab treatment and ipilimumab treatment Approximately 19 months
Secondary overall response rate (ORR) Approximately 19 months
Secondary best overall response rate (BORR) Approximately 19 months
Secondary overall survival (OS) Approximately 19 months
Secondary progression-free survival (PFS) Approximately 19 months
Secondary incidence of treatment-related adverse events (AEs) incidence of treatment-related adverse events (AEs)/adverse reactions (ARs) Approximately 19 months
Secondary severity of treatment-related adverse events (AEs) severity of treatment-related adverse events (AEs)/adverse reactions (ARs) Approximately 19 months
See also
  Status Clinical Trial Phase
Recruiting NCT05094804 - A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents Phase 1/Phase 2
Completed NCT03979872 - Risk Information and Skin-cancer Education for Undergraduate Prevention N/A
Recruiting NCT04986748 - Using QPOP to Predict Treatment for Sarcomas and Melanomas
Enrolling by invitation NCT00068003 - Harvesting Cells for Experimental Cancer Treatments
Recruiting NCT05707286 - Pilot Study to Determine Pro-Inflammatory Cytokine Kinetics During Immune Checkpoint Inhibitor Therapy
Active, not recruiting NCT05470283 - Phase I, Open-Label, Study of Tumor Infiltrating Lymphocytes Engineered With Membrane Bound IL15 Plus Acetazolamide in Adult Patients With Metastatic Melanoma Phase 1
Recruiting NCT05077137 - A Feasibility Study Utilizing Immune Recall to Increase Response to Checkpoint Therapy Phase 1
Active, not recruiting NCT02721459 - XL888 + Vemurafenib + Cobimetinib for Unresectable BRAF Mutated Stage III/IV Melanoma Phase 1
Completed NCT00341939 - Retrospective Analysis of a Drug-Metabolizing Genotype in Cancer Patients and Correlation With Pharmacokinetic and Pharmacodynamics Data
Recruiting NCT05839912 - Excision of Lymph Node Trial (EXCILYNT) (Mel69) N/A
Recruiting NCT04971499 - A Study of Dapansutrile Plus Pembrolizumab in Patients With PD-1 Refractory Advanced Melanoma Phase 1/Phase 2
Recruiting NCT05263453 - HL-085+Vemurafenib to Treat Advanced Melanoma Patients With BRAF V600E/K Mutation Phase 2
Active, not recruiting NCT05060432 - Study of EOS-448 With Standard of Care and/or Investigational Therapies in Participants With Advanced Solid Tumors Phase 1/Phase 2
Not yet recruiting NCT06413680 - A First-In Human (FIH) Trial to Find Out if REGN10597 is Safe and How Well it Works for Adult Participants With Advanced Solid Organ Malignancies Phase 1/Phase 2
Terminated NCT03399448 - NY-ESO-1-redirected CRISPR (TCRendo and PD1) Edited T Cells (NYCE T Cells) Phase 1
Completed NCT03348891 - TNF in Melanoma Patients Treated With Immunotherapy N/A
Completed NCT03171064 - Exercise as a Supportive Measure for Patients Undergoing Checkpoint-inhibitor Treatment Phase 2
Not yet recruiting NCT05539118 - Interferon-α1b Combined With Toripalimab and Anlotinib Hydrochloride in Advanced Unresectable Melanoma Phase 1/Phase 2
Recruiting NCT05171374 - pRospective Evaluation of Clinical Outcomes in Patients With metAsTatIс melanOma Treated With dabrafeNib and trAmetinib in reaL practicE
Withdrawn NCT02854488 - Yervoy Pregnancy Surveillance Study

External Links